Ossein hydroxyapatite ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 1 |
75. Cushing disease
Clinical trials : 203 / Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-002280-14-FR (EUCTR) | 18/07/2008 | 06/06/2008 | Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial | Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial | The Active substance of Osteopor is Ossein Hydroxyapatite.Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. MedDRA version: 9.1;Level: LLT;Classification code 10006956;Term: Calcium deficiency | Trade Name: OSTEOPOR Product Name: OSTEOPOR Product Code: L0006CP03A INN or Proposed INN: ossein hydroxyapatite Trade Name: OROCAL Product Name: OROCAL INN or Proposed INN: calcium carbonate | Pierre Fabre Médicament | NULL | Not Recruiting | Female: yes Male: no | 60 | Phase 3 | France |